Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
复制标题
DOI：
10.1186/1479-5876-7-45
复制
发表时间：
2009-06-17
影响因子：
7.4
通讯作者：
Marincola FM
中科院分区：
文献类型：
--
作者：
Tahara H;Sato M;Thurin M;Wang E;Butterfield LH;Disis ML;Fox BA;Lee PP;Khleif SN;Wigginton JM;Ambs S;Akutsu Y;Chaussabel D;Doki Y;Eremin O;Fridman WH;Hirohashi Y;Imai K;Jacobson J;Jinushi M;Kanamoto A;Kashani-Sabet M;Kato K;Kawakami Y;Kirkwood JM;Kleen TO;Lehmann PV;Liotta L;Lotze MT;Maio M;Malyguine A;Masucci G;Matsubara H;Mayrand-Chung S;Nakamura K;Nishikawa H;Palucka AK;Petricoin EF;Pos Z;Ribas A;Rivoltini L;Sato N;Shiku H;Slingluff CL;Streicher H;Stroncek DF;Takeuchi H;Toyota M;Wada H;Wu X;Wulfkuhle J;Yaguchi T;Zeskind B;Zhao Y;Zocca MB;Marincola FM
在国家癌症研究所（NCI）国际事务办公室的支持下，于2009年3月举办了“美日肿瘤学免疫生物标志物研讨会”。该研讨会与国际癌症生物治疗学会（iSBTc）和美国食品和药物管理局（FDA）发起的工作组有关，旨在确定生物治疗领域生物标志物发现和验证的策略。这项工作将在2009年10月28日的“iSBTc-FDA-NCI癌症预后和预测性免疫生物标志物研讨会”上达到高潮，该研讨会将与年会一起在华盛顿举行。美日研讨会的目的是：a）讨论在癌症免疫治疗中加强发现预测和/或预后标志物的新方法; B）定义生物标志物发现和验证的科学状态。日本和美国科学家的参与为确定两国之间不同的免疫遗传背景和不同的疾病流行率的共同或不一致的主题提供了机会。融合的概念被确定：增强干扰素相关途径的知识被认为是理解免疫介导的组织特异性破坏（TSD）的核心，其中肿瘤排斥反应是一个代表性的方面。尽管干扰素刺激基因（ISG）的表达可能介导导致肿瘤排斥的炎症过程，但其本身是不够的，相关机制需要确定。适应性免疫应答在肿瘤排斥中可能比与其抗原特异性严格相关的免疫应答发挥更广泛的作用;可能的是，它们的主要作用是在肿瘤部位触发急性和组织特异性炎症应答，这导致在募集额外的先天性和适应性免疫机制时发生排斥。其他候选的全身和/或组织特异性生物标志物被认为可能被添加到适用于免疫治疗试验的已知实体列表中。人们认识到需要一种利用强大的高通量技术的生物标志物发现的系统方法;从目前的科学状况来看，很明显免疫疗法仍处于发现阶段，目前只有少数生物标志物值得广泛验证。最后，很明显，虽然目前的技术具有几乎无限的潜力，但研究设计不足、实验室之间的标准化和交叉验证有限以及数据可比性欠佳仍然是主要障碍。建立一个自愿参与的高通量临床试验分子监测互动联盟可能提供具有成本效益的解决方案。
Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.
登录
查看更多内容
影响因子：
11.5
作者：
Badoual, C;Hans, S;Tartour, E
通讯作者：
Tartour, E
影响因子：
5.4
作者：
Bigger, CB;Guerra, B;Lanford, RE
通讯作者：
Lanford, RE
影响因子：
11.5
作者：
Atkins, M;Regan, M;Signoretti, S
通讯作者：
Signoretti, S
影响因子：
25.7
作者：
Ahlenstiel, Golo;Nischalke, Hans Dieter;Nattermann, Jacob
通讯作者：
Nattermann, Jacob
DOI：
10.1084/jem.20021553
发表时间：
2003-03-17
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Bennett L;Palucka AK;Arce E;Cantrell V;Borvak J;Banchereau J;Pascual V
通讯作者：
Pascual V